Introduction

The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has reshaped modern medicine, public health, and global socioeconomic dynamics. While the acute manifestations of COVID-19 ranging from asymptomatic infection to severe respiratory failure have been extensively studied, attention has increasingly shifted toward the persistent and often debilitating symptoms that linger long after the resolution of acute infection [1].

This condition, widely referred to as Long COVID or post-acute sequelae of SARS-CoV-2 infection (PASC), represents one of the most pressing post-pandemic challenges.

Long COVID is not a single disease entity but rather a heterogeneous syndrome encompassing multiple organ systems. Patients report a broad range of symptoms including chronic fatigue, post-exertional malaise, dyspnea, chest pain, palpitations, cognitive impairment (often described as “brain fog”), sleep disturbances, anosmia, dysautonomia, and musculoskeletal pain [2]. Psychiatric symptoms such as anxiety, depression, and post-traumatic stress disorder (PTSD) are also common, further complicating the clinical picture [3].

These manifestations may persist for weeks, months, or even years following the initial infection, significantly impairing quality of life and productivity. Epidemiological estimates vary, but studies suggest that between 10–30% of individuals infected with SARS-CoV-2 develop some form of prolonged symptoms. Considering the scale of the pandemic, this translates into tens of millions of individual’s worldwide living with the consequences of Long COVID.

From a pathophysiological perspective, Long COVID presents a unique puzzle [4]. Traditional models of post-viral syndromes, such as those following Epstein-Barr virus or influenza infection, offer partial analogies, yet the scope and severity of Long COVID exceed previous observations. Multiple overlapping mechanisms have been proposed. Persistent viral reservoirs may continue to drive immune activation and inflammation even in the absence of detectable viremia. Dysregulated immune responses including altered T-cell function, persistent cytokine elevations, and the presence of autoantibodies suggest a sustained state of immune imbalance [5]. Furthermore, SARS-CoV-2 is recognized for its vascular tropism, and evidence of endothelial damage, microvascular thrombosis, and impaired nitric oxide signaling highlight the importance of vascular dysfunction in symptom persistence. Neurological and autonomic pathways appear particularly vulnerable, with many patients experiencing postural orthostatic tachycardia syndrome (POTS), neuropathic pain, and cognitive deficits likely stemming from neuroinflammation and microvascular compromise [6].

Mitochondrial dysfunction has also emerged as a central hypothesis in the pathogenesis of Long COVID. Persistent inflammation and oxidative stress impair mitochondrial energy production, leading to reduced ATP availability and abnormal metabolic responses to exertion. This mechanism aligns with the hallmark symptom of post-exertional malaise, drawing parallels to myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Additionally, psychosocial factors such as chronic stress, trauma, and social determinants of health may exacerbate symptoms and prolong recovery, while epigenetic modifications induced by SARS-CoV-2 could sustain immune and metabolic dysregulation.

The multisystem nature of Long COVID requires a broad lens for both research and clinical management. Unlike acute COVID-19, which was primarily approached through respiratory and critical care frameworks, Long COVID spans pulmonology, cardiology, neurology, psychiatry, immunology, and rehabilitation medicine. The challenge lies in both understanding the underlying biology and translating this knowledge into effective treatment strategies. Current management is largely symptomatic and multidisciplinary, focusing on rehabilitation, supportive care, and psychosocial interventions. Symptom-directed therapies such as pacing for fatigue, pulmonary rehabilitation for dyspnea, beta-blockers or ivabradine for dysautonomia, and cognitive rehabilitation for brain fog form the cornerstone of care. Pharmacological approaches remain experimental, with ongoing trials investigating immunomodulatory, antivirals, anticoagulants, and metabolic support therapies [7].

Despite these emerging strategies, significant gaps remain in our understanding. The absence of universally accepted diagnostic criteria complicates both clinical care and research efforts. Biomarker discovery is urgently needed to identify subgroups of patients with distinct pathophysiological mechanisms, allowing for more personalized interventions. Moreover, the trajectory of Long COVID is highly variable: while some individuals experience gradual improvement, others report worsening or relapsing symptoms, and a subset may face lifelong disability. This variability underscores the importance of longitudinal studies and patient registries to map outcomes over time.

The implications of Long COVID extend far beyond individual health. At a societal level, the syndrome imposes a heavy burden on healthcare systems, economies, and labor markets [8].

Millions of individuals are unable to return to work at full capacity, contributing to workforce shortages and economic disruption. Healthcare systems must adapt to meet the needs of patients requiring long-term, multidisciplinary care. Social safety nets and workplace accommodations will play critical roles in mitigating the broader impact. Furthermore, Long COVID amplifies existing health inequities, disproportionately affecting marginalized populations who face barriers to healthcare access, financial instability, and increased exposure to the virus due to occupational and environmental factors.

The scientific community is mobilizing to address these challenges, but the task is formidable. Understanding the pathophysiology of Long COVID requires integration across multiple disciplines virology, immunology, vascular biology, neurology, psychiatry, and systems biology. The search for effective treatments will necessitate innovative clinical trial designs that account for the heterogeneity of symptoms and mechanisms. Patient advocacy groups have also played a crucial role in shaping the research agenda, emphasizing the importance of lived experiences and highlighting symptoms that may otherwise be overlooked [9].

In this context, the purpose of this paper is twofold: first, to provide a comprehensive analysis of the pathophysiological mechanisms thought to underlie Long COVID, and second, to evaluate current and emerging management strategies. By synthesizing the latest evidence, this work aims to contribute to the development of a coherent framework for understanding and addressing Long COVID. While much remains uncertain, the rapid progress in research offers hope that targeted, effective interventions will emerge. Ultimately, addressing Long COVID is not only a medical necessity but also a societal imperative. As the acute phase of the pandemic subsides, the long-term sequelae will define the next chapter in our global response to COVID-19.

In summary, Long COVID embodies the complexities of a post-viral syndrome at unprecedented scale. It challenges existing paradigms of infectious disease, immunity, and chronic illness, while simultaneously demanding novel approaches to clinical care and health policy. A deeper understanding of its mechanisms and management strategies will be essential for reducing its long-term impact on individuals, healthcare systems, and societies worldwide [10].

Pathophysiological Mechanisms

Persistent Viral Reservoirs

Evidence suggests that SARS-CoV-2 RNA and proteins may persist in tissues such as the gut, CNS, and lymphoid organs. Residual viral antigens can maintain a state of chronic immune activation, promoting inflammation and tissue injury.

 Immune Dysregulation

Many patients with Long COVID display altered immune profiles, including elevated pro-inflammatory cytokines (IL-6, TNF-α), aberrant T-cell activation, and impaired interferon responses. These mechanisms overlap with autoimmune processes, and autoantibodies against G-protein coupled receptors and endothelial antigens have been identified in some patients [11].

Endothelial Dysfunction and Microvascular Injury: SARS-CoV-2 has strong tropism for endothelial cells via ACE2 receptors, leading to endotheliitis and microvascular thrombosis. Long COVID patients often present with endothelial dysfunction, reduced nitric oxide bioavailability, and micro clot formation, which may underlie persistent fatigue, exercise intolerance, and neurological sequelae.

Dysautonomia and Neurological Involvement: A significant proportion of patients develop postural orthostatic tachycardia syndrome (POTS), neuropathic pain, or cognitive impairment. These may result from autonomic nervous system imbalance, neuroinflammation, or microvascular compromise of the central nervous system [12].

Mitochondrial Dysfunction and Metabolic Derangements: Persistent systemic inflammation impairs mitochondrial function, leading to reduced ATP production and altered oxidative metabolism. This mechanism explains the hallmark symptom of post-exertional malaise in Long COVID, paralleling findings in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

Psychosocial and Epigenetic Factors: Chronic stress, trauma, and socioeconomic vulnerability contribute to symptom persistence and exacerbation. Moreover, epigenetic modifications induced by viral infection may alter immune and metabolic pathways, sustaining chronicity.

 Clinical Manifestations

Long COVID manifests heterogeneously across organ systems:

ü  Respiratory: dyspnea, reduced lung diffusion capacity, pulmonary fibrosis in some cases.

ü  Neurological: cognitive dysfunction, sleep disturbances, anosmia, Dysautonomia.

ü  Cardiovascular: palpitations, myocarditis sequelae, arrhythmias, micro thrombotic events.

ü  Musculoskeletal: myalgia, arthralgia, chronic fatigue.

ü  Psychiatric: anxiety, depression, post-traumatic stress.

 Management Strategies

Symptom-Based Clinical Management

ü  Fatigue & Exercise Intolerance: pacing and energy conservation techniques, graded rehabilitation programs with caution to avoid post-exertional symptom exacerbation.

ü  Respiratory Symptoms: pulmonary rehabilitation, breathing exercises, inhaled corticosteroids when indicated [13].

ü  Cardiovascular & Autonomic Dysfunction: beta-blockers, ivabradine, volume expansion, and salt supplementation for POTS-like symptoms.

ü  Neurocognitive Symptoms: cognitive rehabilitation, occupational therapy, and pharmacologic interventions under study (e.g., stimulants, low-dose naltrexone).

 Pharmacological Interventions

Anti-inflammatory & Immunomodulatory Therapies: ongoing trials explore corticosteroids, colchicine, and biologics targeting IL-6 or TNF-α.

Anticoagulant & Antiplatelet Strategies: low-dose anticoagulation may benefit patients with evidence of micro clot pathology.

Antiviral Therapy: Pavlova and other antivirals are being tested for their potential in clearing persistent viral reservoirs.

Multidisciplinary and Holistic Approaches

Long COVID, or post-acute sequelae of SARS-CoV-2 infection (PASC), represents one of the most significant and enduring challenges of the pandemic era. While the acute phase of COVID-19 drew immediate attention due to its high morbidity and mortality, the long-term burden of persistent symptoms is only now being fully appreciated. The condition is marked by heterogeneity in presentation, duration, and severity, making it a complex clinical and scientific problem. A comprehensive conclusion must therefore reflect both the biological complexity and the broader societal implications of Long COVID [14].

From a mechanistic perspective, the evidence indicates that Long COVID is driven by a confluence of overlapping factors rather than a single causal pathway. Persistent viral reservoirs in tissue, immune dysregulation with sustained cytokine release, endothelial and microvascular dysfunction, mitochondrial impairment, and autonomic nervous system imbalance appear to contribute to the clinical phenotype. These biological insights not only explain the multisystem involvement but also highlight why patients experience such varied symptoms ranging from fatigue and “brain fog” to cardiovascular instability and psychiatric disturbances. Importantly, Long COVID shares similarities with other post-viral syndromes, such as ME/CFS, while also demonstrating unique features related to SARS-CoV-2’s endothelial and vascular tropism.

In terms of management, no universal therapy has yet emerged, and current strategies rely primarily on a multidisciplinary and holistic framework. Symptom-based care remains the cornerstone of treatment, with approaches including pacing and energy conservation for fatigue, pulmonary rehabilitation for respiratory complaints, pharmacological treatment for dysautonomia, and cognitive rehabilitation for neurocognitive impairments. Integrative care models involving pulmonologists, cardiologists, neurologists, psychiatrists, immunologists, and rehabilitation specialists are increasingly recognized as essential. Emerging pharmacologic interventions such as immunomodulatory, antivirals aimed at clearing viral reservoirs, and anticoagulants to address microvascular pathology offer hope but remain under investigation. Nutritional and mitochondrial support therapies also show potential, though evidence is still preliminary [15].

One of the most striking lessons of Long COVID is the necessity of bridging biomedical treatment with psychosocial support. Patients frequently encounter disbelief, stigma, and a lack of recognition within healthcare systems, which exacerbates suffering. Mental health care, workplace accommodations, and patient-centered rehabilitation programs must therefore form integral parts of management. Equally critical is the recognition of health inequities: Long COVID disproportionately impacts vulnerable and marginalized populations, amplifying preexisting social and economic disparities. Addressing this inequity requires systemic changes in healthcare delivery, access, and policy.

The socioeconomic implications of Long COVID are profound. With millions worldwide experiencing prolonged illness, workforce participation has declined, productivity has been disrupted, and healthcare systems face unprecedented demand for long-term care. This reality underscores the need for policymakers to treat Long COVID not just as a medical condition but as a public health and economic issue. Investments in rehabilitation infrastructure, disability support systems, and long-term monitoring programs are crucial. Failure to address these dimensions’ risks entrenching the pandemic’s legacy into a chronic societal burden [16].

Looking forward, several research priorities must guide the global response. First, consensus on diagnostic criteria is urgently needed to improve clinical recognition and standardize research efforts. Second, biomarker discovery should be prioritized to stratify patients into subgroups, enabling personalized interventions. Third, longitudinal cohort studies are essential to clarify the natural history of Long COVID, identifying predictors of recovery versus chronicity. Fourth, innovative clinical trial designs must account for the heterogeneity of symptoms and mechanisms, ensuring that promising treatments are tested across different patient subtypes. Finally, collaboration between clinicians, researchers, policymakers, and patient advocacy groups will be key to sustaining momentum and ensuring that research aligns with patient needs.

Despite the uncertainties, progress has been made. The rapid mobilization of the scientific community has led to growing insights into the immunological, vascular, and neurological underpinnings of Long COVID. The recognition of its overlap with other post-viral syndromes opens avenues for shared research and therapeutic strategies. Moreover, patient advocacy movements have played a transformative role in driving awareness and shaping research agendas, ensuring that lived experiences inform scientific inquiry [1].

Ultimately, Long COVID serves as a reminder of the long shadow pandemics can cast. It challenges conventional boundaries between infectious disease and chronic illness, highlighting the need for adaptive healthcare systems capable of responding to emerging syndromes. Addressing Long COVID requires more than symptom management it demands a rethinking of how societies support individuals with chronic, poorly understood conditions. By integrating biomedical, psychosocial, and policy approaches, it is possible to mitigate its burden and foster resilience in the face of ongoing uncertainty.

In conclusion, Long COVID is not merely a medical curiosity but a multidimensional phenomenon with far-reaching implications. Its pathophysiology underscores the interconnectedness of viral persistence, immune dysregulation, vascular injury, and metabolic dysfunction, while its clinical impact reflects the vulnerabilities of both individuals and societies. Multidisciplinary and holistic approaches are essential to managing its complexity, but lasting solutions will depend on sustained research, equitable healthcare delivery, and global cooperation. As the world transitions out of the acute crisis of COVID-19, Long COVID will remain a defining challenge of the post-pandemic era one that requires vision, compassion, and scientific innovation to overcome [17].

Emerging and Experimental Approaches

ü  Plasmapheresis & Apheresis: aimed at removing autoantibodies and micro clots.

ü  Mitochondrial Support Therapies: supplementation with CoQ10, NAD+, and antioxidants under investigation.

ü  Immunotherapy: targeted biologics for autoimmunity-driven subgroups.

 Challenges and Future Directions

Research on Long COVID remains in early stages, with heterogeneity in definitions, diagnostic criteria, and outcome measures. Biomarker discovery, patient stratification, and personalized medicine approaches are crucial. Large-scale longitudinal studies are needed to distinguish transient post-viral syndromes from chronic, progressive disease. Moreover, the socioeconomic and public health impacts of Long COVID necessitate investment in rehabilitation infrastructure and workplace accommodations [18].

 Discussion

Post-acute sequelae of SARS-CoV-2 infection (PASC), commonly known as Long COVID, represents a complex, multisystem syndrome characterized by diverse biological mechanisms. This complexity makes it difficult to identify a single causal pathway or a universal therapeutic approach. In this discussion, the main pathophysiological mechanisms are summarized, followed by a comparative review of selected studies, supported with tables highlighting similarities, differences, and research gaps.

Summary of Key Mechanisms: Systematic reviews and mechanistic studies point to several overlapping contributors: (1) persistent viral reservoirs or antigens driving chronic inflammation, (2) immune dysregulation and production of autoantibodies, (3) endothelial damage and microvascular pathology, particularly fibrinaloid micro clots, (4) mitochondrial dysfunction leading to impaired energy metabolism, and (5) neurological involvement and dysautonomia. Evidence suggests that these mechanisms often coexist, producing distinct clinical subgroups rather than a single phenotype.

Microclots and Coagulation Pathophysiology: Work from Pretorius, Kell, and others has highlighted the potential role of amyloid-like fibrinaloid microclots and fibrinogen abnormalities in driving fatigue, impaired microcirculation, and reduced tissue oxygen delivery. This line of inquiry has generated considerable interest, offering a novel explanatory model. However, critics emphasize the need for standardized assays and independent replication before establishing causality [19].

Autoantibodies and Immune Dysregulation: Multiple studies and systematic reviews report functional autoantibodies particularly against G-protein coupled receptors (GPCRs) and renin-angiotensin system components in subsets of Long COVID patients. While causality is not firmly established, these findings raise the possibility that certain patients may benefit from immune-modulatory approaches or pathogenetic removal strategies (e.g., apheresis). Reproducibility across different research centers, however, remains incomplete.

Pharmacological Interventions Prevention vs. Treatment: Observational evidence suggests that early administration of viral replication inhibitors such as nirmatrelvir/ritonavir may reduce the risk of developing Long COVID, with large cohort studies supporting this claim. In contrast, trials of the same drugs as treatment for chronic Long COVID have produced mixed results. For example, a Stanford RCT testing a 15-day Pavlova regimen in chronic patients showed no significant benefit compared to placebo. This discrepancy suggests that antivirals may be more effective in prevention during the acute phase than as curative therapy for established chronic disease. Timing, treatment duration, and patient stratification may be key determinants of efficacy [20].

Overlap with ME/CFS and Implications for Rehabilitation: Many Long COVID features such as persistent fatigue, post-exertional malaise, and cognitive impairment mirror those of other post-infectious syndromes, particularly myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). This overlap creates both opportunities and challenges. On one hand, ME/CFS research offers valuable rehabilitation insights that may be adapted for Long COVID care. On the other, the ME/CFS experience highlights the risks of poorly tailored interventions; rehabilitation strategies must be individualized and carefully monitored to avoid exacerbating symptoms.

 Table 1. Mechanistic and Review Studies

Table 2. Therapeutic and Preventive Evidence

 Implications for Research and Clinical Care: Several priorities emerge from this comparative analysis: